| Literature DB >> 33879786 |
Giulia Della Chiara1,2,3,4, Federica Gervasoni1,2,3,4, Michaela Fakiola1,2, Chiara Godano2,3,5, Claudia D'Oria1,2,3,4, Luca Azzolin6, Raoul Jean Pierre Bonnal1,2, Giulia Moreni2,7, Lorenzo Drufuca1,2, Grazisa Rossetti1,2, Valeria Ranzani2, Ramona Bason1,2,4, Marco De Simone2,8, Francesco Panariello4,9, Ivan Ferrari4, Tanya Fabbris2, Francesca Zanconato6, Mattia Forcato10, Oriana Romano10, Jimmy Caroli10, Paola Gruarin2, Maria Lucia Sarnicola2, Michelangelo Cordenonsi6, Alberto Bardelli11,12, Nicola Zucchini13, Andrea Pisani Ceretti14, Nicolò Maria Mariani14, Andrea Cassingena15, Andrea Sartore-Bianchi15,16, Giuseppe Testa3,16,17, Luca Gianotti18, Enrico Opocher14,19, Federica Pisati20, Claudio Tripodo21,22, Giuseppe Macino23, Salvatore Siena15,16, Silvio Bicciato10, Stefano Piccolo24,25, Massimiliano Pagani26,27,28,29.
Abstract
Cancer is characterized by pervasive epigenetic alterations with enhancer dysfunction orchestrating the aberrant cancer transcriptional programs and transcriptional dependencies. Here, we epigenetically characterize human colorectal cancer (CRC) using de novo chromatin state discovery on a library of different patient-derived organoids. By exploring this resource, we unveil a tumor-specific deregulated enhancerome that is cancer cell-intrinsic and independent of interpatient heterogeneity. We show that the transcriptional coactivators YAP/TAZ act as key regulators of the conserved CRC gained enhancers. The same YAP/TAZ-bound enhancers display active chromatin profiles across diverse human tumors, highlighting a pan-cancer epigenetic rewiring which at single-cell level distinguishes malignant from normal cell populations. YAP/TAZ inhibition in established tumor organoids causes extensive cell death unveiling their essential role in tumor maintenance. This work indicates a common layer of YAP/TAZ-fueled enhancer reprogramming that is key for the cancer cell state and can be exploited for the development of improved therapeutic avenues.Entities:
Year: 2021 PMID: 33879786 DOI: 10.1038/s41467-021-22544-y
Source DB: PubMed Journal: Nat Commun ISSN: 2041-1723 Impact factor: 14.919